We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+2.16%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.73B
AUM Growth
+$336M
Cap. Flow
+$448M
Cap. Flow %
25.88%
Top 10 Hldgs %
59.34%
Holding
67
New
13
Increased
7
Reduced
17
Closed
3

Top Buys

Rank Stock Value
1
ALXO icon
ALX Oncology
ALXO
+$166M
2
HRMY icon
Harmony Biosciences
HRMY
+$165M
3
NVAX icon
Novavax
NVAX
+$20M
4
CYTK icon
Cytokinetics
CYTK
+$16.4M
5
MREO
Mereo BioPharma
MREO
+$15.9M

Top Sells

Rank Stock Value
1
VSTM icon
Verastem
VSTM
+$7.98M
2
LEGN icon
Legend Biotech
LEGN
+$7.57M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$4.7M
4
GLMD icon
Galmed Pharmaceuticals
GLMD
+$4.11M
5
RNAC icon
Cartesian Therapeutics
RNAC
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 91.47%
2 Financials 6.31%
3 Materials 2.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
26
DELISTED
Avadel Pharmaceuticals
AVDL
$17.8M 1.03%
3,526,093
– –
KNSA icon
27
Kiniksa Pharmaceuticals
KNSA
$6.09B
$17.6M 1.02%
1,151,622
– –
AKRO
28
DELISTED
Akero Therapeutics
AKRO
$17.6M 1.02%
571,833
-19,336
-3% -$676K
CDXS icon
29
Codexis
CDXS
$156M
$17.3M 1%
1,476,289
-17,614
-1% -$219K
MREO
30
Mereo BioPharma
MREO
$48.4M
$16.3M 0.94%
6,220,938
+5,442,938
+700% +$15.9M
NKTX icon
31
Nkarta
NKTX
$157M
$15.4M 0.89%
+512,225
New +$15.1M
CYTK icon
32
Cytokinetics
CYTK
$10.7B
$15.2M 0.88%
+700,000
New +$16.4M
CBAY
33
DELISTED
Cymabay Therapeutics
CBAY
$15.1M 0.87%
2,089,356
– –
ZGNX
34
DELISTED
Zogenix, Inc.
ZGNX
$14.7M 0.85%
817,935
+159,412
+24% +$3.91M
EIGR
35
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$14.6M 0.84%
59,709
– –
CALT
36
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$13.9M 0.8%
580,000
– –
KDNY
37
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$12.4M 0.72%
1,023,712
– –
LRMR icon
38
Larimar Therapeutics
LRMR
$426M
$12.1M 0.7%
799,662
– –
EPIX
39
DELISTED
ESSA Pharma
EPIX
$10.5M 0.6%
+1,516,865
New +$10.3M
ZLAB icon
40
Zai Lab
ZLAB
$2.07B
$10.2M 0.59%
122,107
– –
QTTB icon
41
Q32 Bio
QTTB
$491M
$9.13M 0.53%
47,397
-1,253
-3% -$281K
MTNB icon
42
Matinas BioPharma
MTNB
$1.76M
$8.64M 0.5%
225,586
– –
PSTX
43
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$8.22M 0.47%
+926,449
New +$10.5M
CVAC
44
DELISTED
CureVac
CVAC
$7.91M 0.46%
+169,825
New +$9.47M
IGMS
45
DELISTED
IGM Biosciences
IGMS
$7.64M 0.44%
103,480
-16,000
-13% -$947K
AUPH icon
46
Aurinia Pharmaceuticals
AUPH
$1.95B
$7.38M 0.43%
500,732
– –
OVID icon
47
Ovid Therapeutics
OVID
$489M
$7.17M 0.41%
+1,250,000
New +$8.36M
DYN icon
48
Dyne Therapeutics
DYN
$4.89B
$6.36M 0.37%
+315,000
New +$6.91M
KALA icon
49
KALA BIO
KALA
$13.6M
$5.9M 0.34%
315
– –
LONA
50
LeonaBio Inc
LONA
$72.1M
$5.54M 0.32%
+30,000
New +$5.01M
1
2
3

Similar funds

FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return
KOC
Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Vivo Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Vivo Capital held 67 positions worth $1.73B, up 24% from $1.39B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Vivo Capital deployed $448M of net new capital in Q3 2020, opening 13 new positions and adding to 7 existing holdings. Its largest new stake was ALX Oncology: 4,220,048 shares worth $159M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Legend Biotech, an estimated $7.57M trimmed.

  • Vivo Capital's largest Q3 2020 buy was ALX Oncology: 4,220,048 shares worth $159M.
  • Vivo Capital added most to Mereo BioPharma in Q3 2020, an estimated $15.9M increase.
  • Vivo Capital's biggest Q3 2020 reduction was Legend Biotech, cutting an estimated $7.57M.
  • Vivo Capital fully exited Verastem in Q3 2020, selling an estimated $7.98M.
  • Vivo Capital's ten largest holdings make up 59% of its $1.73B portfolio in Q3 2020.
  • Vivo Capital opened 13 new positions and closed 3 in Q3 2020.
  • Vivo Capital's portfolio value rose 24% quarter-over-quarter to $1.73B.

Based on Vivo Capital's 13F filing for Q3 2020, filed 13 Nov 2020.